MaxCyte, Inc. Preclinical Results at ASGCT Annual Meeting
21 5월 2018 - 3:01PM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
21 May 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting
Showing Correction of Sickle Cell Disease Mutation in Hematopoietic
Stem Cells
- Data demonstrate the potential of MaxCyte's technologies in
non-viral CRISPR gene correction for the treatment of sickle cell
disease
Gaithersburg, Maryland - 21 May 2018: MaxCyte (LSE: MXCT, MXCR),
the global cell-based medicines and life sciences company, today
announced that preclinical data for its non-viral CRISPR-mediated
gene-correction of sickle cell mutation in hematopoietic stem cells
(HSC) from a sickle cell disease (SCD) patient were presented at
the annual meeting of the American Society of Gene and Cell Therapy
(ASGCT) in Chicago on Friday, 18 May 2018.
The new data were presented in a poster presentation, entitled
"GMP-compliant non-viral CRISPR-mediated process correcting the
sickle cell disease mutation in SCD patient CD34+ cells achieves
60% wild type adult hemoglobin expression in differentiated
erythrocytes." The data from work with the National Institutes of
Health's (NIH) National Heart Lung and Blood Institute (NHLBI)
demonstrated the potential of MaxCyte's technologies and the
non-viral CRISPR gene correction in the treatment of SCD.
"We're encouraged that MaxCyte's technology is at the forefront
of enabling non-viral CRISPR-mediated correction of disease
mutations at clinically-relevant levels," said Doug Doerfler,
MaxCyte Chief Executive Officer. "We're excited by these results
for their potential to bring therapeutic benefit to individuals
living with SCD."
The abstract can be found at the ASGCT meeting website at
annualmeetingasgct.com/am18/abstracts and the presentation is
available via
https://www.maxcyte.com/resource-center/posters-presentations/.
About Sickle Cell Disease
According to the NHLBI, sickle cell disease (SCD) describes a
group of inherited red blood cell disorders. Patients with SCD have
abnormal hemoglobin, called hemoglobin S or sickle hemoglobin, in
their red blood cells. Hemoglobin is a protein in red blood cells
that carries oxygen throughout the body. Those who have SCD inherit
two abnormal hemoglobin genes, one from each parent. In all forms
of SCD, at least one of the two abnormal genes cause a person's
body to make hemoglobin S.
Sickle cell disease is a life-long illness. The severity of the
disease varies widely from person to person. In high-income
countries like the United States, according to NHLBI, the life
expectancy of a person with SCD is now about 40-60 years.
Currently, hematopoietic stem cell transplantation (HSCT) is the
only cure for SCD. Unfortunately, most people with SCD are either
too old for a transplant or don't have a relative who is a good
enough genetic match for them to act as a donor. A well-matched
donor is needed to have the best chance for a successful
transplant. While there are some treatments that can reduce
symptoms and prolong life, more medical options are needed.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology to
enable its partners across the biopharmaceutical industry to
advance the development of innovative medicines, particularly in
cell therapy, including gene editing and immuno-oncology. The
Company has placed its cutting-edge flow electroporation
instruments worldwide, including with nine of the top ten global
biopharmaceutical companies, and has more than 50 partnered
programme licences in cell therapy including more than 20 licensed
for clinical use. With its robust delivery technology, MaxCyte
helps its partners to unlock the full potential of their
products.
For more information, visit www.maxcyte.com.
###
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley
Emma Earl
Ryan McCarthy
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABSGDULDBBGII
(END) Dow Jones Newswires
May 21, 2018 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024